Drug
[18F]Florbetapir
[18F]Florbetapir is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph early_phase_1
3
60%
Ph not_applicable
1
20%
Ph phase_2
1
20%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Early Phase 1First-in-human
3(60.0%)
Phase 2Efficacy & side effects
1(20.0%)
N/ANon-phased studies
1(20.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(3)
Terminated(1)
Other(1)
Detailed Status
Completed3
Withdrawn1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Early Phase 13 (60.0%)
Phase 21 (20.0%)
N/A1 (20.0%)
Trials by Status
withdrawn120%
unknown120%
completed360%
Recent Activity
0 active trials
Showing 5 of 5
completedearly_phase_1
Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein
NCT03071224
unknownphase_2
Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination
NCT04305210
completedearly_phase_1
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
NCT03058965
withdrawnnot_applicable
Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics
NCT03641768
completedearly_phase_1
Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
NCT03080051
Clinical Trials (5)
Showing 5 of 5 trials
NCT03071224Early Phase 1
Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein
NCT04305210Phase 2
Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination
NCT03058965Early Phase 1
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
NCT03641768Not Applicable
Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics
NCT03080051Early Phase 1
Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5